Toxicology

TFF Pharmaceuticals and Augmenta Bioworks Publish Positive In Vivo Data Showing Dry Powder Formulation of COVID-19 Antibody, AUG-3387, Neutralizes SARS-CoV-2 Infection and Reduces Viral Load

Thursday, October 14, 2021 - 1:30pm

AUSTIN, Texas and MENLO PARK, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, and Augmenta Bioworks, a biotechnology company leveraging immune profiling technologies to enable breakthroughs in medicine, today announced the publication of a research paper highlighting positive preclinical study results of AUG-3387, a monoclonal antibody (mAb) therapy being developed in collaboration between the two companies for the treatment of SARS-CoV-2 infection. The findings have been published online through the bioRxiv preprint server, under the title “AUG-3387, a Human-Derived Monoclonal Antibody Neutralizes SARS-CoV-2 Variants and Reduces Viral Load from Therapeutic Treatment of Hamsters In Vivo.”

Key Points: 
  • Delivery of the dry powder formulation of AUG-3387 to infected hamsters resulted in a dose-dependent reduction of viral load when administration of the mAb was initiated 24 hours after infection with SARS-CoV-2.
  • This study also represents the first report of successful reduction of viral load using inhaled delivery of a dry powder monoclonal antibody therapeutic for COVID-19 disease.
  • In addition to the in vivo efficacy, AUG-3387 also showed binding activity against the Alpha, Beta, Delta, Gamma, Kappa, Lambda and Mu variants of SARS-CoV-2.
  • TFF Pharmaceuticals has two lead drug candidates: Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder.

A Practical Roadmap for IND-Enabling Safety and Toxicology Studies, Upcoming Webinar Hosted by Xtalks

Thursday, October 14, 2021 - 1:30pm

Preclinical toxicology studies should reliably assess the safety of new drug entities, thus building a multi-faceted understanding of compounds to lay the groundwork for clinical trials and regulatory approval.

Key Points: 
  • Preclinical toxicology studies should reliably assess the safety of new drug entities, thus building a multi-faceted understanding of compounds to lay the groundwork for clinical trials and regulatory approval.
  • In this webinar, our featured speaker will present a roadmap that seamlessly integrates the various preclinical studies, thus accelerating the initiation of clinical trials.
  • Register for this webinar to learn about the best way to plan for investigational new drug (IND)-enabling preclinical toxicology studies.
  • For more information, or to register for this event, visit A Practical Roadmap for IND-Enabling Safety and Toxicology Studies.

Insights on the Life Science Microscopy Devices Global Market to 2029 - Microscopy Demand Spiked During COVID-19 Pandemic - ResearchAndMarkets.com

Wednesday, October 13, 2021 - 4:55pm

The global life science microscopy devices market is expected to grow at a CAGR of 10%.

Key Points: 
  • The global life science microscopy devices market is expected to grow at a CAGR of 10%.
  • Growing trend of microscopy application in life science research contribute growth to the life science microscopy devices market.
  • What is the key impact of Covid-19 over market revenues and market determinants in the Life science microscopy devices market?
  • Who are the key players in the Life science microscopy devices market and what are their key product categories and strategies?

Chocolate Isn't the Only Scary Thing Threatening Your Pet This Halloween

Wednesday, October 13, 2021 - 3:05pm

When Stats returned home from work, she found the empty bag and several areas where Charlotte had vomited with significant chocolate evidence.

Key Points: 
  • When Stats returned home from work, she found the empty bag and several areas where Charlotte had vomited with significant chocolate evidence.
  • In the process of treating her for chocolate poisoning, they were able to determine that Charlotte had been suffering from exocrine pancreatic insufficiency (EPI)."
  • "This is an extremely toxic and potentially fatal dose of chocolate," said Dr. Ahna Brutlag, a board-certified veterinary toxicologist at Pet Poison Helpline.
  • In addition to chocolate, pet lovers should keep any candy sweetened with xylitol away from their animals.

Richard Kho, PhD, and Murali Gopal, MD, Join Iterative Scopes in Senior Leadership Roles

Wednesday, October 13, 2021 - 1:30pm

Iterative Scopes is working on an important mission to dramatically improve patient outcomes in the field of gastroenterology through the use of computer vision and AI, said Dr. Kho.

Key Points: 
  • Iterative Scopes is working on an important mission to dramatically improve patient outcomes in the field of gastroenterology through the use of computer vision and AI, said Dr. Kho.
  • The earlier that physicians can correctly detect, diagnose, and treat disease, the better off we are as patients and as a healthcare system.
  • Dr. Richard Khos career has focused on combining data and technology to drive positive changes in healthcare.
  • I am very excited to have joined the brilliant individuals here at Iterative Scopes, Dr. Gopal noted.

Regulus Therapeutics Announces Strategic Prioritization of RGLS8429, its Next-Generation Candidate for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Tuesday, October 12, 2021 - 9:05pm

SAN DIEGO, Oct. 12, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the prioritization of its promising, next-generation candidate, RGLS8429, for the treatment of Autosomal Dominant Polycystic Kidney Disease(ADPKD).

Key Points: 
  • SAN DIEGO, Oct. 12, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the prioritization of its promising, next-generation candidate, RGLS8429, for the treatment of Autosomal Dominant Polycystic Kidney Disease(ADPKD).
  • Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs.
  • These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect.
  • Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Accelerating CAR T Development from Preclinical to Clinical Utilizing Key Biomarker Insights, Upcoming Webinar Hosted by Xtalks

Tuesday, October 12, 2021 - 1:30pm

For more information, or to register for this event, visit Accelerating CAR T Development from Preclinical to Clinical Utilizing Key Biomarker Insights.

Key Points: 
  • For more information, or to register for this event, visit Accelerating CAR T Development from Preclinical to Clinical Utilizing Key Biomarker Insights.
  • Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community.
  • Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.)
  • Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

Global In-vitro Toxicology Testing Market Size, Share & Trends Analysis Report 2021 - ResearchAndMarkets.com

Friday, October 8, 2021 - 4:03pm

The "Global In-vitro Toxicology Testing Market Size, Share & Trends Analysis Report by Technology (Cell Culture, High Throughput), by Method, by Application, by End-use (Diagnostics, Chemical Industry, Food Industry), by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global In-vitro Toxicology Testing Market Size, Share & Trends Analysis Report by Technology (Cell Culture, High Throughput), by Method, by Application, by End-use (Diagnostics, Chemical Industry, Food Industry), by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • In recent times, the validation and acceptance of in-vitro and alternative testing methods by regulatory agencies are increasing at lucrative pace.
  • Also, ongoing technological advancements to replace the use of animals for toxicology testing purposes have spurred the use of in vitro testing models, in turn, driving the market.
  • Several companies offer HTT-based in vitro toxicology analysis, e.g., Solidus Bioscience's MetaChip Technology, which provides a solution for in vitro toxicology analysis using HTT.

HTG Expands Therapeutics Team

Tuesday, October 5, 2021 - 1:00pm

TUCSON, Ariz., Oct. 05, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced it has expanded its therapeutics team with the addition of several highly experienced professionals.

Key Points: 
  • TUCSON, Ariz., Oct. 05, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced it has expanded its therapeutics team with the addition of several highly experienced professionals.
  • Our proprietary RNA platform, paired with our advanced medicinal chemistry technologies, has set the stage for HTG to be highly disruptive in drug discovery by developing candidates with superior efficacy and safety profiles, said John Lubniewski, CEO of HTG.
  • Before joining HTG, Dr. Huffman co-founded Padlock Therapeutics, Inc., a biotechnology company dedicated to creating new medicines to treat destructive autoimmune diseases that was subsequently acquired by Bristol-Myers Squibb.
  • HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide profiling to drive translational research, clinical diagnostics and targeted therapeutics across a variety of disease areas.

Cordant Health Solutions Receives Accreditation From College of American Pathologists for 22nd Consecutive Year

Tuesday, October 5, 2021 - 11:00am

FLAGSTAFF, Ariz., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Cordant Health Solutions, a leader in providing innovative tools for monitoring patients in behavioral health programs , has been awarded accreditation by the Accreditation Committee of the College of American Pathologists (CAP) for its laboratory located in Flagstaff.

Key Points: 
  • FLAGSTAFF, Ariz., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Cordant Health Solutions, a leader in providing innovative tools for monitoring patients in behavioral health programs , has been awarded accreditation by the Accreditation Committee of the College of American Pathologists (CAP) for its laboratory located in Flagstaff.
  • Cordant has successfully met the stringent standards for CAP accreditation since September 2000 and is one of only 35 laboratories in the U.S. with accreditation for forensic drug testing (CAP FDT) .
  • Cordant Health Solutions (cordantsolutions.com) provides innovative tools for monitoring behavioral health, chronic pain and criminal justice cases.
  • A leader in quality standards, Cordant provides solutions for payers, clinicians and organizations involved with substance use disorder, pain management and criminal justice agencies.